Therapeutics Company Awarded Patent For Breakthrough Liver Disease Treatment

In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been awarded a new European patent for CM-101, its first-in-class monoclonal antibody, now in Phase 2 clinical development for PSC. This news not only marks a significant milestone for Chemomab but also shines a beacon of hope for patients battling this challenging condition. $ $Chemomab Therapeutics (CMMB.US)$